Agilent xCELLigence multiple-plate, real-time cell analyzer

The National Institutes of Health (NIH) intends to award a Firm-Fixed-Price Purchase Order to Agilent Technologies Inc. for an Agilent xCELLigence multiple-plate, real-time cell analyzer. The CCR Genomics Core, under Dr. Liz Conner, will host the xCELLigence RTCA MP system to support the development of novel cell-based cancer therapies at CCR. The system provides a non-invasive, label-free, impedance-based platform to continuously monitor cell health, behavior, and function over assay windows spanning seconds to days. • The xCELLigence RTCA MP system will be used to support the development of novel cell-based cancer therapies. • The system provides a non-invasive, label-free, impedance-based platform to continuously monitor cell health, behavior, and function. • The CCR Genomics Core will be responsible for scheduling and maintenance of the instrument. • The system has been highlighted as supporting potency assay development in the context of an FDA approval of a CAR T therapy.